Radiopharm Theranostics Ltd (ASX: RAD) Share Price and News

Price

$0.026

Movement

0.00 (0.0)

as at 13 Jun - Closed (20 mins delayed)

52 Week Range

$0.019 - $0.048

 
1 Year Return

-13.33%

Radiopharm Theranostics Ltd Chart and Price Data

2025
2025
2025
2025
$0.00
$0.02
$0.04
$0.00
$0.02
$0.04
$0.00
$0.02
$0.04
$0.00
$0.02
$0.04

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $60.68 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 2.33 billion
Earnings per share -0.062
Dividend per share N/A
Year To Date Return 8.33%
Earnings Yield N/A
Franking -
Share Price

$0.026

Day Change

0.00 (0.0)

52 Week Range

$0.019 - $0.048

Yesterday's Close

$0.026

Today's Open

$0.027

Days Range

$0.024 - $0.027

Volume

3,221,392

Avg. Volume (1 month)

2,948,857

Turnover

$81,993

as at 13 Jun - Closed

  • Radiopharm Theranostics Ltd (ASX: RAD)
    Latest News

    A boy stands firm on a rocky cliff holding a rocket in each hand and looking up toward the sky, anticipating flying into space.
    Small Cap Shares

    2 ASX small-cap shares rocketing 35% to 54% today

    Two soaring ASX small-cap shares are setting the bar high on Friday.

    Read more »

    one hundred dollar notes planted in the ground representing growth asx shares
    Small Cap Shares

    'Richest pipeline' in ASX: Expert names 3 small-cap shares to buy

    Ask A Fund Manager: Alto Capital's Tony Locantro also reveals what his biggest regret in investing is.

    Read more »

    RAD ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    12th Jun 2025 2025-06-12T08:30:33 Notice Under Section 708AYesNo8:30am178k
    12th Jun 2025 2025-06-12T08:24:13 Application for quotation of securities - RADYesNo8:24am616k
    11th Jun 2025 2025-06-11T08:24:00 RAD Granted US FDA Fast Track for RAD101 Metastases ImagingYesNo8:24am2111k
    10th Jun 2025 2025-06-10T17:35:49 Proposed issue of securities - RADYesNo5:35pm515k
    4th Jun 2025 2025-06-04T08:26:48 RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202YesNo8:26am2116k
    2nd Jun 2025 2025-06-02T09:14:56 RAD Reports Positive Preclinical Lu177-B7H3-mAb DataYesNo9:14am3272k
    30th May 2025 2025-05-30T18:37:56 Change of Director's Interest Notice (IT)YesNo6:37pm3218k
    19th May 2025 2025-05-19T08:23:30 ITM and RAD Sign Supply Agreement for n.c.a. Lutetium-177YesNo8:23am2126k
    12th May 2025 2025-05-12T08:46:04 Acceleration of RAD204 Phase 1 dose escalation trialYesNo8:46am2211k
    29th Apr 2025 2025-04-29T10:15:17 Quarterly Activities/Appendix 4C Cash Flow ReportYesNo10:15am95.9M

    About Radiopharm Theranostics Ltd

    Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.

    RAD Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    12 Jun 2025 $0.03 $0.00 0.00% 2,966,032 $0.03 $0.03 $0.03
    11 Jun 2025 $0.03 $0.00 0.00% 4,830,681 $0.03 $0.03 $0.03
    10 Jun 2025 $0.02 $0.00 0.00% 1,440,587 $0.03 $0.03 $0.02
    06 Jun 2025 $0.03 $0.00 0.00% 1,706,880 $0.03 $0.03 $0.03
    05 Jun 2025 $0.03 $0.00 0.00% 482,848 $0.03 $0.03 $0.03
    04 Jun 2025 $0.03 $0.00 0.00% 5,807,351 $0.03 $0.03 $0.03
    03 Jun 2025 $0.03 $0.00 0.00% 832,680 $0.03 $0.03 $0.03
    02 Jun 2025 $0.03 $0.00 0.00% 5,207,569 $0.03 $0.03 $0.03
    30 May 2025 $0.02 $0.00 0.00% 2,334,624 $0.02 $0.02 $0.02
    29 May 2025 $0.02 $0.00 0.00% 2,090,500 $0.03 $0.03 $0.02
    28 May 2025 $0.03 $0.00 0.00% 784,120 $0.03 $0.03 $0.02
    27 May 2025 $0.03 $0.00 0.00% 4,324,114 $0.02 $0.03 $0.02
    26 May 2025 $0.02 $0.00 0.00% 13,533,677 $0.02 $0.02 $0.02
    23 May 2025 $0.02 $0.00 0.00% 3,177,180 $0.02 $0.02 $0.02
    22 May 2025 $0.02 $0.00 0.00% 59,386 $0.02 $0.02 $0.02
    21 May 2025 $0.02 $0.00 0.00% 5,731,219 $0.02 $0.02 $0.02
    20 May 2025 $0.02 $0.00 0.00% 1,760,924 $0.02 $0.02 $0.02
    19 May 2025 $0.02 $0.00 0.00% 447,097 $0.02 $0.02 $0.02
    16 May 2025 $0.02 $0.00 0.00% 2,703,301 $0.02 $0.02 $0.02
    15 May 2025 $0.02 $0.00 0.00% 1,924,068 $0.02 $0.02 $0.02
    14 May 2025 $0.02 $0.00 0.00% 163,204 $0.02 $0.02 $0.02

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    23 May 2025 Ian Turner Buy 3,000,000 $87,000
    On-market trade. $0.029 ea. average
    19 Feb 2025 Ian Turner Buy 1,300,000 $33,800
    On-market trade.
    16 Dec 2024 Ian Turner Issued 12,040,404 $325,090
    Issue of options.
    16 Dec 2024 Riccardo Canevari Buy 684,787 $19,858
    On-market trade.
    16 Dec 2024 Riccardo Canevari Issued 7,091,615 $219,840
    As advised by the company. Issuance of shares per pre-employment
    contract.
    16 Dec 2024 Riccardo Canevari Issued 55,250,286 $1,491,757
    Issue of options.
    16 Dec 2024 Hester Larkin Issued 8,000,000 $216,000
    Issue of options.
    16 Dec 2024 Phillip Hains Issued 8,000,000 $216,000
    Issue of options.
    16 Dec 2024 Paul Hopper Issued 8,000,000 $216,000
    Issue of options.
    16 Dec 2024 Leila Alland Issued 8,000,000 $216,000
    Issue of options.
    16 Dec 2024 Noel Donnelly Issued 8,000,000 $216,000
    Issue of options.
    05 Dec 2024 Paul Hopper Sell 1,500,000 $43,037
    On-market trade.
    18 Oct 2024 Ian Turner Buy 333,864 $9,348
    On-market trade.
    13 Sep 2024 Leila Alland Issued 500,000 $15,000
    Placement.
    13 Sep 2024 Leila Alland Issued 1,000,000 $40,000
    Placement.
    13 Sep 2024 Ian Turner Issued 1,875,000 $56,250
    Placement.
    13 Sep 2024 Ian Turner Issued 2,250,000 $90,000
    Placement.
    13 Sep 2024 Ian Turner Issued 1,500,000 $60,000
    Placement.
    13 Sep 2024 Paul Hopper Issued 27,500,000 $825,000
    Placement.
    13 Sep 2024 Paul Hopper Issued 55,000,000 $2,200,000
    Placement.
    13 Sep 2024 Phillip Hains Issued 9,700,000 $388,000
    Placement.
    13 Sep 2024 Phillip Hains Issued 4,850,000 $145,500
    Placement.
    13 Sep 2024 Riccardo Canevari Issued 3,750,000 $150,000
    Placement.
    13 Sep 2024 Riccardo Canevari Issued 25,875,000 $776,250
    Placement.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Phillip Hains Chief Financial OfficerJoint Company SecretaryNon-executive director Mar 2024
    Mr Hains has over 30 years of experience in roles with a portfolio of ASX and NASDAQ listed companies.
    Mr Paul Alex Hopper Executive ChairmanFounderExecutive Director Feb 2021
    Mr. Hopper brings 20 years' experience in the management and funding of biotechnology and healthcare companies in Australia and the United States. Former directorships in last 3 years: Scopus BioPharma Inc (NASDAQ: SCPS), until 18 May 2022.
    Mr Ian Turner Non-Executive Director Apr 2021
    Mr Turner, since August 2022, is also non-executive director at AtomVie Global Radiopharma Inc, a global contract development and manufacturing organization, launched by the Centre for ProbeDevelopment and Commercialisation (CPDC). Mr. Turner was a director of Coqui Pharmaceuticals from November 2014 to March 2019. Mr.Turner was Chief Executive Officer at Siemens Radiopharmaceuticals, which operated a global PET radio-pharmacy network, from 2010 to 2012. Prior to that, he was General Manager of ANSTO Radiopharmaceuticals, which was Australia's manufacturer of radioisotopes for the nuclear medicine sector. Since 2013, Mr. Turner is the CEO of the Turner Group LLC, a boutique management consulting firm that advises institutional investors on acquisition targets in the field of nuclear medicine, radiochemicals and radiopharmaceuticals He chairs risk committee.
    Mr Riccardo Canevari Chief Executive OfficerManaging Director Sep 2021
    Mr.Canevari was previously Chief Commercial Officer of Novartis company, Advanced Accelerator Applications, from April 2020 to September2021, one of the radiopharmaceutical and nuclear medicine companies globally. He was responsible for commercial strategy and country organizations in approximately 20 countries across North America, Europe and Asia. Prior to that, he was Senior Vice President and Global Head of the Breast Cancer Franchise for Novartis Oncology from 2017, where he oversaw the launch of breast cancer products. Mr. Canevari has also held management roles with Novartis Pharma and Ethicon/Johnson & Johnson.
    Ms Hester Larkin Non-Executive Director Feb 2022
    Ms. Larkin is currently the Managing Director of Hester Larkin Associates Consulting. Since 2008 in this role, she has been providing consulting services to diagnostic imaging, pharmaceutical and biotech companies in projects ranging from pre-clinical, clinical, submission to the European Medicines Agency, EU medical advisory boards, EU manufacturing and commercial partnerships. Ms. Larkin has also held several board director and trustee positions in the United Kingdom and Belgium and currently sits on the board of directors of two charities. Prior to this, Ms. Larkin was the EMA General Manager BMS Medical Imaging at Bristol-Myers Squibb from 2002 to 2008 and held roles in European marketing, European business development and general management at DuPont Pharmaceuticals from 1983 to 2008. She is member of risk committee.
    Dr Leila Alland Non-Executive Director Jun 2022
    Dr. Alland is a biotech advisor working with entrepreneurs and investors to advance diagnostic and therapeutic products for oncology and rare diseases. Dr. Alland also serves on the board of directors of Abeona Therapeutics (NASDAQ: ABEO), a cell and gene therapy company. Previously, Dr. Alland served as CMO of PMV Pharma (NASDAQ, PMVP),an oncology company, and prior to that, as CMO of Affimed (NASDAQ: AFMD), an immuno-oncology company, and as CMO of Tarveda Therapeutics, a targeted drug conjugate company. Her career includes leadership roles at AstraZeneca, Bristol-Myers Squibb, Novartis and Schering-Plough, where she contributed to the development and approvals of Tagrisso, Opdivo, Tasigna, and Caelyx. As Head of Oncology Early Clinical Development at AstraZeneca, she oversaw the company's early oncology portfolio. She completed training in Pediatrics at the Children's Hospital of Philadelphia, and Hematology/Oncology at MemorialSloan-Kettering, and served on the faculty of Albert Einstein College of Medicine. She is Member of risk committee.
    Mr Noel Donnelly Non-Executive Director Oct 2024
    Mr Donnelly brings over 25 years of leadership experience in finance, strategy, and operations within the biopharmaceutical and biotechnology industries. He has a track record of building and leading cross-functional teams, driving corporate governance, and executing complex financial strategies that support rapid company growth. Currently serving as Chief Financial Officer at PepGen Inc. Before joining PepGen, Mr Donnelly was CFO at EIP Pharma (now CervoMed. His career also includes a 15-year tenure at Takeda/Shire PLC, where he held various senior roles, including Vice President of R&D Business Operations. In addition to his operational expertise, Mr Donnelly is experienced in business partnering, valuation, investor relations, and decision support analysis, making him a trusted advisor to both executive leadership teams and boards of directors.
    Mr Nathan Jong Joint Company Secretary
    -
    Thom Tulip Chief Business Officer
    -
    David Mozley Chief Medical Officer
    -
    Vittorio Puppo Chief Operating Officer
    -
    Nathan Jong Joint Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 504,532,102 23.22%
    Neweconomy Com Au Nominees Pty Limited 175,379,974 8.07%
    Ubs Nominees Pty Ltd 150,154,505 6.91%
    Lantheus Omega Llc Wholly Owned Subsidiary Of Lantheus Holdings Inc 149,625,180 6.89%
    J P Morgan Nominees Australia Pty Limited 147,212,899 6.77%
    Hsbc Custody Nominees (Australia) Limited 103,073,463 4.74%
    National Nominees Limited 58,318,057 2.68%
    Paul Hopper 55,400,000 2.55%
    BNP Paribas Noms Pty Ltd 46,796,456 2.15%
    Nanomab Technology Limited 43,295,131 1.99%
    Warbont Nominees Pty Ltd 41,339,514 1.90%
    Dulyne Pty Ltd 32,500,000 1.50%
    Morgan Stanley Australia Securities (Nominee) Pty Limited 25,007,765 1.15%
    Bnp Paribas Nominees Pty Ltd 24,322,347 1.12%
    Scarlett Hopper 23,857,142 1.10%
    Hsbc Custody Nominees (Australia) Limited A/C 2 23,190,887 1.07%
    HSBC Custody Nominees 22,440,879 1.03%
    Palm Beach Nominees Pty Limited 19,023,940 0.88%
    Buttonwood Nominees Pty Ltd 16,850,001 0.78%
    Shared Office Services Pty Ltd 15,839,358 0.73%

    Profile

    since

    Note